NCT02993133

Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: University Hospital, Limoges · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main autoimmune bullous dermatoses are pemphigus and cicatricial pemphigoid. Pemphigus is an autoimmune dermatological disease characterized by the production of anti-desmoclesin antibodies 1 and 3, affecting the skin and mucous membranes.The cicatricial pemphigoid is an autoimmune dermatological disease, characterized by the production of anti-zone antibodies of the basal membrane and characterized by a predominant mucosal involvement. Mycophenolic acid (MPA) is an increasingly used form of corticosteroid. Despite its increasing use, pharmacokinetics in autoimmune bullous dermatosis remain little studied.

Conditions

• Autoimmune Bullous Dermatose

Interventions

Type	Name	Description
DRUG	Cellcept® in autoimmune bullous dermatoses	The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses

Timeline

• Start date: 2016-12-01
• Primary completion: 2019-01-01
• Completion: 2019-04-01
• First posted: 2016-12-15
• Last updated: 2019-04-22

Locations

3 sites across 1 country: France